Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

@article{Vaddi2012RuxolitinibAO,
  title={Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis},
  author={Kris Vaddi and Nicholas J. Sarlis and Vikas Gupta},
  journal={Expert Opinion on Pharmacotherapy},
  year={2012},
  volume={13},
  pages={2397 - 2407}
}
Introduction: Myelofibrosis (MF) is a debilitating hematologic malignancy characterized by progressive splenomegaly, burdensome symptoms, cytopenias and shortened survival. Chronic alterations in Janus-associated kinase-signal transducer and activator of transcription (JAK-STAT) signaling have been identified in the pathogenesis of MF, making this pathway a target for drug development. Ruxolitinib is the first JAK1 and JAK2 inhibitor to be approved by the US Food and Drug Administration. Areas… 
Triggering of Suicidal Erythrocyte Death by Ruxolitinib
TLDR
Ruxolitinib triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect in part requiring p38 MAP kinase activity.
Baricitinib: From Rheumatoid Arthritis to COVID‐19
TLDR
The significant efficacy of baricitinib, versus the probable adverse effects, urge further investigation before establishing it as a part of standard therapeutic protocols.
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
TLDR
Ruxolitinib could provide a treatment backbone to which other (conventional and novel) therapies may be added for the prevention and effective management of specific MF-associated complications and the possibility of a disease-modifying effect.
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
TLDR
This is the first case report that shows the effects of ruxolitinib in a splenectomized patient with primary myelofibrosis, which transformed to acute myeloblastic leukemia, and the patient died 1 month later.
Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
TLDR
The recent progress concerning JAK inhibition is reviewed, including the innovations provided by the release of JAKs crystal structures and the improvement of synthetic strategies aimed to simplify of the industrial scale-up.
Selective JAK inhibitors in development for rheumatoid arthritis
  • P. Norman
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 2014
TLDR
A review of the clinical development and available clinical results for those JAK inhibitors currently under investigation and the preclinical data on these, in addition to peficitinib, ABT-494, INCB-047986 and AC-410.
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
TLDR
In both models, treatment with the JAK1/2 inhibitor ruxolitinib significantly lessened the clinical and laboratory manifestations of HLH, including weight loss, organomegaly, anemia, thrombocytopenia, hypercytokinemia, and tissue inflammation.
Old Drugs for JAK-STAT Pathway Inhibition in COVID-19
TLDR
The docking results indicated that naproxen, methadone, and amitriptyline, considering their higher binding energy, lower energy variance, and higher hydrophobicity, seem to express more inhibitory effects on Janus kinase enzymes than for approved inhibitors i.e. baricitinib and ruxolitinib.
...
1
2
3
4
...

References

SHOWING 1-10 OF 41 REFERENCES
Ruxolitinib for the treatment of myelofibrosis: its clinical potential
TLDR
Longer follow-up of the phase III MF studies is needed to reach firm conclusions regarding ruxolitinib’s capacity to modify the natural disease course, as well as risks of potentially serious adverse effects, eg, myelosuppression.
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
TLDR
A risk-adapted approach individualized to each patient's biologic characteristics and comorbidities is described, which is currently warranted in determining optimal treatment strategies for patients with myelofibrosis.
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
TLDR
Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
TLDR
In a mouse model of JAK2V617F(+) MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppression effects.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
TLDR
Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
TLDR
INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed, and clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myel ofibrosis.
Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy
TLDR
Additional post hoc analyses from the COMFORT-II study further support that ruxolitinib improves overall HRQoL and MF symptoms compared with overall BAT, and assesses changes from baseline in HRQeL andMF symptom scores, including the EORTC subscales, LymS, and FACT total scores, which incorporate well-being and/or symptom subscales.
Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,
TLDR
Changes in SV as low as 10% in ruxolitinib-treated patients were associated with improvements on EORTC QLQ-C30 Global Health subscale, PROMISE Fatigue scale, and the MFSAF v2.0 diary TSS, and commensurate improvements in these outcomes were observed as the SV reduction increased.
Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
TLDR
Pacritinib shows promising efficacy in alleviating MF-associated splenomegaly and constitutional symptoms at a dose that induces minimal myelosuppression, and is chosen as the recommended dose (RD) for Phase 2 study.
Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study
TLDR
Ruxolitinib was shown to be more effective than BAT at reducing spleen volume in all patient subgroups regardless of gender, age, mutation status, IPSS risk category, baseline spleen size, MF subtype, or ruxolit inib starting dose.
...
1
2
3
4
5
...